A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
This is a study for participants with advanced gastric or gastroesophageal junction
adenocarcinoma who had tumor progression after first-line treatment with platinum and
fluoropyrimidine doublet therapy. The study will be conducted in 2 parts.